| Literature DB >> 34012284 |
Koenraad De Boulle1, Nobutaka Furuyama2, Izolda Heydenrych3,4, Terrence Keaney5, Alexander Rivkin6, Vincent Wong7, Michael Silberberg8.
Abstract
There is increasing demand among transgender individuals for minimally invasive aesthetic procedures, such as injectable facial fillers and neurotoxins, for facial remodeling and transformation. These procedures may increase transgender individuals' satisfaction with their appearance and allow them to more effectively harmonize their physical appearance with their perception of self. There is currently a lack of information in the medical literature regarding guidelines for the use of these products in transgender patients. In this report, the authors provide experience-based treatment considerations and recommendations for use of minimally invasive facial aesthetic procedures in transgender patients, including case studies illustrating the use of these procedures for both male-to-female and female-to-male transitioning patients. This report highlights the success of minimally invasive methods for assisting transgender patients in achieving their facial remodeling goals. Clinicians play an integral role in the transitioning process for transgender patients, and facial transformation is a key element of this process. When conducted with sensitivity and attention to individual patient goals at varying stages of transition, facial procedures can be of great benefit in enhancing patients' self-perception and overall quality of life.Entities:
Keywords: hyaluronic acid; neurotoxins; transgender persons
Year: 2021 PMID: 34012284 PMCID: PMC8128506 DOI: 10.2147/CCID.S304032
Source DB: PubMed Journal: Clin Cosmet Investig Dermatol ISSN: 1178-7015
Facial Aesthetic Goals for Transitioning Individuals9,15
| Ideal Female Face | Ideal Male Face |
|---|---|
| Large, smooth forehead with some convexity and arched eyebrows | Wider forehead with horizontal brow and prominent supraorbital ridge |
| Eyes that appear wide open | Deeper-set eyes that appear close together |
| Proportionally smaller, narrow nose with upturned nasal tip | Proportionally larger, wider, more projected nose |
| Obtuse nasofrontal angle | Less obtuse nasofrontal angle |
| Obtuse nasolabial angle | Less obtuse nasolabial angle |
| Heart-shaped taper in lower face with smaller lower-to-upper face ratio | More equal ratio of lower-to-upper face proportions |
| Prominent, full cheeks and cheekbones | Squared lower face and jaw |
| Full lips, especially anteroposterior axis | Wider mouth with thinner lips |
| Rounded, narrow, proportionally short chin | Long, square, flat chin |
Figure 1Schematic of facial aesthetic goals for transitioning individuals. Based on Table 1, the ideal female face has the following features: (A) Large, smooth forehead with some convexity and arched eyebrows, (B) Eyes that appear wide open, (C) Proportionally smaller, narrow nose with upturned nasal tip, (D) Obtuse nasofrontal angle, (E) Obtuse nasolabial angle, (F) Heart-shaped taper in lower face with smaller lower-to-upper face ratio, (G) Prominent, full cheeks and cheekbones, (H) Full lips, especially anteroposterior axis, and (I) Rounded, narrow, proportionally short chin. The ideal male face has the following features: (A) Wider forehead with horizontal brow and prominent supraorbital ridge, (B) Deeper-set eyes that appear close together, (C) Proportionally larger, wider, more projected nose, (D) Less obtuse nasofrontal angle, (E) Less obtuse nasolabial angle, (F) More equal ratio of lower-to-upper face proportions, (G) Squared lower face and jaw, (H) Wider mouth with thinner lips, and (I) Long, square, flat chin.
Potential Uses of Injectable Fillers and Toxins for Facial Remodeling in Transitioning Individuals
| Recommendations From Upper to Lower Face | ||
|---|---|---|
| Facial Remodeling Goals | Dermal Fillers | Neuromodulators |
| Male to Female | Inject into forehead at the supraperiosteal level to help treat deep furrows and achieve a smooth, gently convex contour; | Inject into forehead, glabellar, or periorbital areas to eliminate dynamic rhytids and create a more feminine forehead, angled eyebrow shape, and widened eyes; |
| Inject along zygomatic arch to help cheeks appear more prominent and contoured; inject into anterior malar area to create a prominent, full, and more feminine apex peaking more superiorly and laterally | Atrophy the glabellar musculature to help create a more obtuse nasofrontal angle; | |
| Inject medially into chin to give it a more-rounded, less-square contour | Inject into the masseter and mentalis muscles to cause gradual atrophy, decreasing the prominence of the male jawline and making the face appear more heart shaped | |
| Inject into lips to augment them | ||
| Address signs of aging such as temple volume loss, marionette hollowing, prejowl sulcus, and tear trough development | ||
| Female to Male | Inject into supraorbital ridge to increase brow line prominence | Inject into the medial and lateral frontalis to help cause an arched brow to drop, resulting in a more masculine appearance |
| Inject uniformly along the zygomatic arch, inferior and medial to the malar prominence, to help broaden the malar base and reduce anterior projection of the apex | ||
| Inject at various points along the radix, dorsum, sidewall, tip, and columella to help broaden the nose, | ||
| Inject into the chin, jawline, mandibular angle, and preauricular area to help define the jaw, enhance the angle of the mandible, and create a more prominent, square, and angular lower part of the face | ||
Figure 2Facial transformation in a 40-year-old male-to-female transgender patient who received onabotulinumtoxinA and dermal fillers to feminize the face. Photographs were taken 2 months post-treatment. Patient images provided by Alexander Rivkin, MD.
Figure 3Full-face transition of a 25-year-old male-to-female transgender patient who received onabotulinumtoxinA and dermal fillers to feminize the face. (A) Colored dots and arrows indicate injection points with corresponding concentrations of onabotulinumtoxinA or filler injected. (B) The patient before (left) and 3 months after (right) treatment. Patient images provided by Vincent Wong, MD.
Figure 4Masculinization of the jawline with repeated VYC-20L injections in a 42-year-old female-to-male transgender patient. (A) Colored dots and arrows indicate injection points with corresponding concentrations of filler injected. (B) The patient before (left) and 4 months after (right) treatment. Patient images provided by Koenraad De Boulle, MD.
Figure 5Female-to-male jawline and chin enhancement in a 19-year-old patient who received VYC-25L. (A) Colored dots and arrows indicate injection sites with corresponding concentrations of filler injected. (B) The patient before (top) and immediately after (bottom) treatment. Photographs were taken immediately following treatment. Patient images provided by Vincent Wong, MD.
Figure 6Feminization of the eyebrow using onabotulinumtoxinA in a patient in his late 20s. The patient before (left) and 2 weeks after (right) treatment. Patient images provided by Terrence Keaney, MD.
Figure 7Feminization of the lips using HYC-24L in a patient in his early 60s. The patient before (left) and 2 weeks after (right) treatment. Patient images provided by Terrence Keaney, MD.